Structure-activity exploration of a small-molecule Lipid II inhibitor

被引:9
|
作者
Fletcher, Steven [1 ]
Yu, Wenbo [1 ,2 ]
Huang, Jing [1 ,2 ]
Kwasny, Steven M. [3 ]
Chauhan, Jay [1 ]
Opperman, Timothy J. [3 ]
MacKerell, Alexander D., Jr. [1 ,2 ]
de Leeuw, Erik P. H. [4 ,5 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Pharm, Comp Aided Drug Design Ctr, Baltimore, MD 21201 USA
[3] Microbiotix Inc, Worcester, MA USA
[4] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
来源
基金
美国国家卫生研究院;
关键词
computer-aided drug design; Lipid II; antibiotics; phospholipid; GENERAL FORCE-FIELD; PEPTIDOGLYCAN-BIOSYNTHESIS; STAPHYLOCOCCUS-AUREUS; CHARMM; ANTIBIOTICS; MECHANISM; BINDING; VALIDATION; AUTOMATION; DEFENSINS;
D O I
10.2147/DDDT.S79504
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]-N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure-activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency.
引用
收藏
页码:2383 / 2394
页数:12
相关论文
共 50 条
  • [41] Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
    Heltweg, B
    Gatbonton, T
    Schuler, AD
    Posakony, J
    Li, HZ
    Goehle, S
    Kollipara, R
    DePinho, RA
    Gu, YS
    Simon, JA
    Bedalov, A
    CANCER RESEARCH, 2006, 66 (08) : 4368 - 4377
  • [42] Structure-activity relationships of small molecule inhibitors of RAGE-Aβ binding
    Ross, Nathan T.
    Deane, Rashid
    Perry, Sheldon
    Miller, Benjamin L.
    TETRAHEDRON, 2013, 69 (36) : 7653 - 7658
  • [43] Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor
    Okamoto, Kiyoshi
    Ito, Daisuke
    Miyazaki, Kazuki
    Watanabe, Saori
    Tohyama, Osamu
    Yokoi, Akira
    Ozawa, Yoichi
    Asano, Makoto
    Kawamura, Takanori
    Yamane, Yoshinobu
    Nagao, Satoshi
    Funasaka, Setsuo
    Kamata, Junichi
    Kotake, Yoshihiko
    Aoki, Mika
    Tsukahara, Naoko
    Mizui, Yoshiharu
    Tanaka, Isao
    Sawada, Kohei
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 29 (04) : 541 - 549
  • [44] A Small-Molecule Inhibitor to the Cytokine Interleukin-4
    Quinnell, Sean P.
    Leifer, Becky S.
    Nestor, Stephen T.
    Tan, Kelly
    Sheehy, Daniel F.
    Ceo, Luke
    Doyle, Shelby K.
    Koehler, Angela N.
    Vegas, Arturo J.
    ACS CHEMICAL BIOLOGY, 2020, 15 (10) : 2649 - 2654
  • [45] Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor
    Yang, Xue
    Huang, Qiaoxian
    Bardelang, David
    Wang, Chunming
    Lee, Simon M. Y.
    Wang, Ruibing
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2017, 15 (38) : 8046 - 8053
  • [46] RAS CAN BE TARGETED BY A MULTIVALENT SMALL-MOLECULE INHIBITOR
    不详
    CANCER DISCOVERY, 2017, 7 (04) : 350 - 350
  • [47] Small-molecule kinase-inhibitor target assessment
    Kung, C
    Shokat, KM
    CHEMBIOCHEM, 2005, 6 (03) : 523 - 526
  • [48] Sunitinib: A newly approved small-molecule inhibitor of angiogenesis
    Cabebe, Elwyn
    Wakelee, Heather
    DRUGS OF TODAY, 2006, 42 (06) : 387 - 398
  • [49] SMALL-MOLECULE CFTR INHIBITOR WITH LOW NANOMOLAR POTENCY
    Snyder, D.
    Tradtrantip, L.
    Yao, C.
    Verkman, A. S.
    PEDIATRIC PULMONOLOGY, 2012, 47 : 239 - 239
  • [50] A Small-Molecule Inhibitor of Hepatitis C Virus Infectivity
    Bush, Caroline O.
    Pokrovskii, Maria V.
    Saito, Roland
    Morganelli, Philip
    Canales, Eda
    Clarke, Michael O.
    Lazerwith, Scott E.
    Golde, Justin
    Reid, Brian G.
    Babaoglu, Kerim
    Pagratis, Nikos
    Zhong, Weidong
    Delaney, William E.
    Paulson, Matthew S.
    Beran, Rudolf K. F.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 386 - 396